FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:1386-1387 May 7, 1998 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Essential mixed cryoglobulinemia (type II) has turned out to be secondary to hepatitis C virus (HCV) infection in the large majority of patients.¹ Interferon is now considered the treatment of choice.^2,3,4,5 It is generally believed that the efficacy of interferon in patients with mixed cryoglobulinemia depends on the suppression of HCV viremia, since viral antigens seem to be a key factor in cryoprecipitates.¹ As a corollary, interferon might be anticipated to be effective only in HCV-associated cryoglobulinemias. In contrast, we found that interferon was highly effective in two HCV-negative patients with true essential type II mixed cryoglobulinemia.

. . . [Full Text of this Article]

References

This article has been cited by other articles:

• Kay, J., McCluskey, R. T. (2005). Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency.. NEJM 353: 1605-1613 [Full Text]  
• Scagnolari, C., Casato, M., Bellomi, F., De Pisa, F., Turriziani, O., Coviello, R., Pirro, M. R., Dianzani, F., Antonelli, G. (2003). Serum Interferon (IFN)-Neutralizing Antibodies and Bioactivities of IFNs in Patients with Severe Type II Essential Mixed Cryoglobulinemia. CVI 10: 70-77 [Abstract] [Full Text]